The State of Utah v. APOTEX CORPORATION; BAXTER HEALTHCARE CORPORATION; BOEHRINGERINGELHEIM CORPORATION; MALLINCKRODT INC.; CSL BEHRING; FOREST LABORATORIES, INC.; MORTON GROVE PHARMACEUTICALS, INC.; MUTUAL PHARMACEUTICAL COMPANY, PNC; NOVARTIS PHARMACEUTICALS CORPORATION; OTSUKA AMERICA, INC.; PFIZER, PNC; QUALITEST PHARMACEUTICALS, PNC; SCHERING-PLOUGH CORPORATION; SCHWARZ PHARMA USA HOLDPNGS, PNC; TARO PHARMACEUTICALS USA, PNC; UPSHER-SMITH, PNC; and WYETH, INC. : Reply Brief

Authors

Utah Supreme Court

Docket Number

20100257.00

Document Type

Reply Brief

Publication Date

2010

Abstract

ADDENDUM TO REPLY BRIEF OE APPELLANT

Comments

Original Brief Submitted to the Utah Supreme Court; digitized by the Howard W. Hunter Law Library, J. Reuben Clark Law School, Brigham Young University, Provo, Utah; machine-generated OCR, may contain errors.
Unknown.
Joseph W. Steele; David C. Biggs; Special Assistant Attorneys General; Steele and Biggs, LLC.

Rights

Public record document (some rights may be reserved).

Recommended Citation

Reply Brief, Utah v. Apotex Corporation, No. 20100257.00 (Utah Supreme Court, 2010).
https://digitalcommons.law.byu.edu/byu_sc2/3032